teva | Neuroscience

Driving the next chapter of neuroscience



Teva has over 30 years of commitment in neurology and psychiatry[1], and is dedicated to bringing innovative solutions where there is high unmet need. Our vision is to collaborate with healthcare professionals to empower patients and caregivers to achieve better health outcomes.

3,700 R&D experts: Dedicated specialists pushing the boundaries of what's possible in neuroscience[1]

21 R&D sites and 48 manufacturing sites: A robust network across approximately 57 markets, ensuring a reliable supply of medicines to patients[2]

29% of our 55 peer-reviewed articles: The proportion specifically focused on neurology or psychiatry in 2024[3]

'Good' is not good enough for patients

- In 2021, **over one-third of the world was living with a neurological condition** - the leading cause of illness and disability globally.[4,5] These conditions threaten the very essence of who we are, changing personalities and lives.[6–9]
- The challenge is similarly acute in psychiatry; according to 2021 data, nearly 1 in 7 people worldwide were living with a mental disorder. This is 1. 1 billion people.[10] Those with severe mental illnesses **face a life expectancy of up to 20 years shorter** than the general population.[11–13]
- This profound effect[4–13] on patients is why, at Teva, we believe 'good' is not good enough. We have a firm commitment to neuroscience, delivering a spectrum of innovative and generic medicines for conditions such as multiple sclerosis, migraine, and schizophrenia. We provide the **scale, reliability of supply, and scientific rigour required to support healthcare professionals' clinical goals and help patients live a better life.**

Growing pipeline

Turning clinical research into reality for patients and carers[14–18]

Extensive generics portfolio

Providing accessible medication globally for neurological and psychiatric conditions[19]

Innovative products

Delivering innovative treatments across a range of neurological and psychiatric conditions - from multiple sclerosis and migraine to schizophrenia[20]

Beyond medicine

We believe in going beyond medical treatment by providing essential resources for healthcare professionals, patients, and their caregivers:

- **NeuroPsych Bytes:** an online platform for healthcare professionals that connects science to clinical practice, offering byte-sized information and a variety of educational resources on neurology and psychiatry
- **Life Effects:** A unique digital platform shaped by patients, for patients, offering real-world insights and inspiration for those navigating neurological and psychiatric conditions

Making patients' and carers' voices heard

Teva supports patients and patient organisations in addressing unmet needs of patients and carers. In 2025, we engaged with groups such as GAMIAN-Europe and EMHA in advocating mental health and migraine across Europe. This included the development of a new communication tool designed to improve dialogue between patients and healthcare professionals.

Get to know Teva in neuroscience
Find out more

EMHA=European Migraine & Headache Alliance; GAMIAN-Europe=Global Alliance of Mental Illness Advocacy Networks-Europe; R&D=research and development.

References:

1. Teva Pharmaceutical Industries Ltd. Innovative Therapeutic Areas. 2024. Available at: https://www.tevapharm.com/science/innovative-therapeutic-areas/. Accessed July 2026.
2. Teva Pharmaceutical Industries Ltd. Company Info: Teva in Facts and Figures. 2024. Available at: https://www.tevapharm.com/our-company/teva-facts-figures/. Accessed July 2026.
3. Teva Pharmaceutical Industries Ltd. 2024 Healthy Future Report: ESG Progress Report. 2024. Available at: https://www.tevapharm.com/globalassets/tevapharm-vision-files/teva-esg-progress-report-2024.pdf. Accessed July 2026.
4. Steinmetz JD, et al. *Lancet Neurol.* 2024;23(4):344–381.
5. World Health Organization. Over 1 in 3 people affected by neurological conditions, leading cause of illness and disability worldwide. 2024. Available at: https://www.who.int/news/item/14-03-2024-over-1-in-3-people-affected-by-neurological-conditions--the-leading-cause-of-illness-and-disability-worldwide. Accessed July 2026.
6. National Multiple Sclerosis Society. Emotional Changes. Available at: https://www.nationalmssociety.org/understanding-ms/what-is-ms/ms-symptoms/emotional-changes. Accessed July 2026.
7. MS Trust. Life changing: mental health and MS. 2023. Available at: https://mstrust.org.uk/news/life-changing-mental-health-and-ms. Accessed July 2026.
8. Bottiroli S, et al. *Pain Res Manag.* 2023;2023:6685372.
9. The Migraine Trust. New research reveals devastating impact of living with migraine, yet condition still not taken seriously. 2024. Available at: https://migrainetrust.org/news/research-devastating-impact-of-migraine/. Accessed July 2026.
10. World Health Organization. Mental disorders. 2025. Available at: https://www.who.int/news-room/fact-sheets/detail/mental-disorders. Accessed July 2026.
11. Thornicroft G. *British Journal of Psychiatry.* 2011;199(6):441–442.
12. Oxford Health Policy Forum. Schizophrenia: Time to Commit to Policy Change 2024 (Report). 2024. Available at: https://www.oxfordhealthpolicyforum.org/wp-content/uploads/2025/01/Schizophrenia-Time-to-Commit-to-Policy-Change-Update-Report-2024-with-endorsers.pdf. Accessed July 2026.
13. Correll C, et al. *World Psychiatry.* 2017;16(2):163–180.
14. Teva Pharmaceutical Industries Ltd. Teva received marketing approval for Copaxone® in the U.K. 2000. Available at: https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2000/Teva-Received-Marketing-Approval-for-Copaxone-in-the-UK/default.aspx. Accessed July 2026.
15. Copaxone. Available at: https://www.copaxone.com/. Accessed July 2026.
16. Teva Pharmaceutical Industries Ltd. Teva's AJOVY® Receives EU Approval Offering Patients the First and Only Anti-CGRP Treatment with Both Quarterly and Monthly Dosing for the Prophylaxis of Migraine in Adults. 2019. Available at: https://www.tevapharm.com/news-and-media/latest-news/tevas-ajovy-receives-eu-approval-offering-patients-the-first-and-only-anti-cgrp-treatment-with-both-qua/. Accessed July 2026.
17. Ajovy. Available at: http://ajovy.com/. Accessed July 2026.
18. Teva Pharmaceutical Industries Ltd. Teva innovative medicine & biosimilar pipeline. 2025. Available at: https://www.tevapharm.com/science/pipeline/. Accessed July 2026.
19. Teva Pharmaceutical Industries Ltd. Generic medicines. 2022. Available at: https://www.tevapharm.com/solutions/generics/. Accessed July 2026.
20. Teva Pharmaceutical Industries Ltd. Neurological conditions take so much: Teva is working to give something back. 2025. Available at: https://www.tevapharm.com/news-and-media/feature-stories/neurological-conditions-take-so-much-teva-neuroscience-expertise/. Accessed August 2026.

Teva Pharmaceuticals Europe B.V. Busweg 1, 2031 DA Haarlem, the Netherlands. Registered No. 003973190 (KvK)

NPS-TPE-NP-01100
August 2026